Cite
HARVARD Citation
Ternov, K. et al. (2022). Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT). European journal of cancer. pp. 75-84. [Online].